{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:28:57Z","timestamp":1793276937262,"version":"4.5.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234065","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T17:48:42Z","timestamp":1591379322000},"page":"e0234065","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":94,"title":["Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"15","author":[{"given":"James","family":"Heyward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-941X","authenticated-orcid":true,"given":"Sonal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-2986","authenticated-orcid":true,"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"pone.0234065.ref001","unstructured":"Centers for Disease Control and Prevention. Prevalence of Both Diagnosed and Undiagnosed Diabetes. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/diagnosed-undiagnosed.html. Accessed March 19, 2019."},{"key":"pone.0234065.ref002","first-page":"451","article-title":"Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.","volume":"40","author":"JF Mosley","year":"2015","journal-title":"P T"},{"key":"pone.0234065.ref003","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes\u2013A systematic review","volume":"140","author":"K R\u00e5dholm","year":"2018","journal-title":"Diabetes Research and Clinical Practice"},{"key":"pone.0234065.ref004","unstructured":"US Food and Drug Administration. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM558427.pdf. Updated May 16, 2017. Accessed October 17, 2017."},{"key":"pone.0234065.ref005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0234065.ref006","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases","volume":"20","author":"PB Ryan","year":"2018","journal-title":"Diabetes, Obesity and Metabolism."},{"issue":"12","key":"pone.0234065.ref007","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study","volume":"20","author":"S Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pone.0234065.ref008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"GK Dawwas","year":"2010","journal-title":"Diabetes, Obesity and Metabolism."},{"key":"pone.0234065.ref009","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients with Type 2 Diabetes.","volume":"178","author":"HY Chang","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"10166","key":"pone.0234065.ref010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"TA Zelniker","year":"2019","journal-title":"Lancet"},{"key":"pone.0234065.ref011","article-title":"Effect of SGLT2 inhibitors for type 2 diabetes on adverse cardiovascular outcomes and amputation versus other oral anti-diabetes medications: a systematic review","author":"J Heyward","year":"2018","journal-title":"PROSPERO- International prospective register of systematic reviews"},{"key":"pone.0234065.ref012","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"JAC Sterne","journal-title":"BMJ"},{"key":"pone.0234065.ref013","article-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses.","author":"GA Wells"},{"key":"pone.0234065.ref014","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"issue":"9","key":"pone.0234065.ref015","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/dom.13352","article-title":"Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.","volume":"20","author":"R Kawamori","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pone.0234065.ref016","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0234065.ref017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/dom.13909","article-title":"Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.","volume":"22","author":"H Sone","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"pone.0234065.ref018","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jdi.12910","article-title":"Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials","volume":"10","author":"D Yabe","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"11","key":"pone.0234065.ref019","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.","volume":"20","author":"P Fioretto","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"pone.0234065.ref020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"SD Wiviott","year":"2019","journal-title":"N Engl J Med Jan 24"},{"issue":"6","key":"pone.0234065.ref021","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.","volume":"7","author":"C Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"pone.0234065.ref022","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med Jun 13"},{"issue":"6","key":"pone.0234065.ref023","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"DR Matthews","year":"2019","journal-title":"Diabetologia Jun"},{"issue":"5","key":"pone.0234065.ref024","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.13213","article-title":"Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP\/INS).","volume":"20","author":"Y Terauchi","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"1","key":"pone.0234065.ref025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13300-017-0354-4","article-title":"Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.","volume":"9","author":"P Hollander","year":"2018","journal-title":"Diabetes Ther"},{"issue":"6","key":"pone.0234065.ref026","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s13300-019-00699-8","article-title":"Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II\/III\/IV Clinical Trials","volume":"10","author":"A Kashiwagi","year":"2019","journal-title":"Diabetes Ther Dec"},{"issue":"1","key":"pone.0234065.ref027","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13300-017-0354-4","article-title":"Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.","volume":"9","author":"P Hollander","year":"2018","journal-title":"Diabetes Ther"},{"issue":"12","key":"pone.0234065.ref028","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study","volume":"20","author":"S Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab Dec"},{"key":"pone.0234065.ref029","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.jval.2019.04.557","article-title":"PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 INHIBITORS: A REAL-WORLD APPROACH.","volume":"22","author":"R Kashambwa","year":"2019","journal-title":"Value in Health"},{"key":"pone.0234065.ref030","doi-asserted-by":"crossref","DOI":"10.2337\/db19-156-OR","article-title":"Risk-benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in routine care of older adults.","volume":"68","author":"E Patorno","year":"2019","journal-title":"Diabetes"},{"issue":"9 Supplement 1","key":"pone.0234065.ref031","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0735-1097(19)32309-5","article-title":"AMPUTATION RISK IN PATIENTS TREATED WITH ANTI-DIABETIC DRUGS INCLUDING SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR AND INCRETINS: A COMPARATIVE REAL-WORLD OUTCOME STUDY","volume":"73","author":"S Paul","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0234065.ref032","first-page":"A71","article-title":"Evaluation of the safety of inhibitors of the co-transporter 2 in a university care hospital","volume":"26","author":"A Pel\u00e1ez Bejarano","year":"2019","journal-title":"European Journal of Hospital Pharmacy"},{"key":"pone.0234065.ref033","first-page":"46","article-title":"SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic","volume":"13","author":"J Sung","year":"2018","journal-title":"J Clin Transl Endocrinol Sep"},{"key":"pone.0234065.ref034","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"P Ueda","year":"2018","journal-title":"Bmj Nov"},{"key":"pone.0234065.ref035","article-title":"Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Lower-Extremity Amputation: Evolving Questions","author":"JY Yang","year":"2019","journal-title":"Evolving Answers Diabetes Obes Metab"},{"key":"pone.0234065.ref036","doi-asserted-by":"crossref","DOI":"10.2337\/db19-1539-P","article-title":"Assessing the risk of amputation with canagliflozin in middle-aged adults and adults over 65 years of age: An observational study using three nationwide databases","volume":"68","author":"M Fralick","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"pone.0234065.ref037","doi-asserted-by":"crossref","first-page":"e00096","DOI":"10.1002\/edm2.96","article-title":"Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study.","volume":"3","author":"JA Udell","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"pone.0234065.ref038","first-page":"S309","article-title":"CANadian CAnagliflozin REgistry (CanCARE): A prospective, observational, assessment of canagliflozin (CANA) treatment in type 2 diabetes; 12 month results.","volume":"61","author":"V Woo","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"pone.0234065.ref039","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.","volume":"20","author":"Z Yuan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pone.0234065.ref040","first-page":"1","article-title":"Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study","author":"K Kaku","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"9 Supplement 1","key":"pone.0234065.ref041","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0735-1097(19)31291-4","article-title":"COMPARATIVE EFFECTIVENESS AND SAFETY OF EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY.","volume":"73","author":"E Patorno","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"pone.0234065.ref042","article-title":"The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study","author":"SJ McGurnaghan","year":"2019","journal-title":"Diabetologia"},{"key":"pone.0234065.ref043","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org"},{"key":"pone.0234065.ref044","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/oxfordjournals.aje.a010035","article-title":"Random-effects meta-analyses are not always conservative","volume":"150","author":"C Poole","year":"1999","journal-title":"Am J Epidemiol"},{"issue":"3","key":"pone.0234065.ref045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40618-019-01103-9","article-title":"Sodium\u2011glucose cotransporter 2 (SGLT\u20112) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta\u2011analysis.","volume":"43","author":"EG Dorsey-Trevi\u00f1o","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"pone.0234065.ref046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2019.05.028","article-title":"Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.","volume":"153","author":"I Dicembrini","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"pone.0234065.ref047","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.","volume":"96","author":"N Katsiki","year":"2019","journal-title":"Metabolism"},{"issue":"3","key":"pone.0234065.ref048","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients","volume":"13","author":"JA Erkens","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Supplement 1","key":"pone.0234065.ref049","article-title":"Association of Diuretics Use and Amputations in Patients with Type 2 Diabetes\u2014A Hypothesis Driven from Canvas Warning?","volume":"67","author":"L Poitier","year":"2018","journal-title":"Diabetes"},{"key":"pone.0234065.ref050","unstructured":"Brooks M. Canagliflozin (Invokana) Gets FDA Nod for CV Protection. MedScape. October 31, 2018. Retrieved from https:\/\/www.medscape.com\/viewarticle\/904201 on September 18, 2019."},{"issue":"2","key":"pone.0234065.ref051","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","article-title":"Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.","volume":"7","author":"O Vardeny","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"Suppl 1","key":"pone.0234065.ref052","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc18-S008","article-title":"Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018.","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"pone.0234065.ref053","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017. Retrieved from https:\/\/www.cdc.gov\/diabetes\/data\/statistics\/statistics-report.html. Accessed September 25, 2019."},{"key":"pone.0234065.ref054","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1745-6215-13-138","article-title":"Drug safety assessment in clinical trials: methodological challenges and opportunities.","volume":"13","author":"S Singh","year":"2012","journal-title":"Trials"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T17:49:16Z","timestamp":1591379356000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234065"}},"subtitle":[],"editor":[{"given":"Jennifer A.","family":"Hirst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234065","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}